This is a working overview of Albumin binding, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-03-29. Anything still debated is marked as such rather than presented as settled.
CJC-1295 belongs to a family of synthetic peptides modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. The compound is built from the first twenty-nine amino acids of the natural human sequence, a fragment that retains full receptor binding capacity. Native growth hormone-releasing hormone is degraded quickly in circulation, so the fragment alone has limited practical value. Early work therefore focused on chemical modifications that preserve receptor binding while slowing enzymatic breakdown. The result is a molecule described in the literature as a long-acting analog of the natural hormone.
Two forms circulate under the CJC-1295 name, and they differ by a single appended group. The version without a drug affinity complex carries four substitutions along the peptide chain, including a D-alanine near the amino terminus and replacements at three other positions. These changes block the enzyme dipeptidyl peptidase IV and remove a methionine residue that is prone to oxidation. The modified fragment is frequently labeled MOD GRF 1-29. Naming conventions are inconsistent across informal sources, which is a common source of confusion.
The albumin-binding version stays in circulation for days, because covalent attachment to serum albumin shields the peptide from rapid filtration and degradation. Reported half-lives for this form fall in the range of several days. The version without the linker is cleared in minutes, with estimates often near thirty minutes in animal work. These figures come from small studies and vary with assay method, species, and route, so they are best read as approximate rather than fixed constants.
Studies in this area generally track growth hormone pulses, insulin-like growth factor 1 concentrations, and occasionally body composition endpoints. Most published human data come from early, small trials, and questions about long-term effects remain open. Whether repeated exposure alters pituitary responsiveness over time is not settled. Analytical work relies on immunoassays for the hormones and on mass spectrometry for the peptide itself, because the two measurements answer different questions.
| Property | Value | Notes |
|---|---|---|
| Target receptor | GHRH receptor (GHRHR) | Expressed on pituitary somatotrophs |
| Primary action | Stimulates growth hormone release | Amplifies pulse size |
| Half-life, albumin-binding form | Several days as reported | Slow release from albumin complex |
| Half-life, unmodified analog | About 30 minutes in animal estimates | Cleared by proteases and filtration |
| Common analytical approach | LC-MS/MS for peptide, immunoassay for hormones | Methods answer different questions |
Reports on this compound commonly follow serum growth hormone and insulin-like growth factor 1 across defined time windows. Protocols differ in sampling frequency, assay platform, and participant characteristics, which makes direct comparison between publications difficult. Some work focuses on pulsatile release patterns instead of average concentrations. Whether repeated exposure alters endogenous hormone rhythms over long periods remains an open question, and the formal literature is thinner than the volume of informal commentary implies.
Once in circulation, the peptide binds the growth hormone-releasing hormone receptor displayed on pituitary somatotroph cells. Receptor activation couples to Gs proteins, elevates intracellular cyclic AMP, and drives protein kinase A signaling inside the cell. That cascade increases discharge of growth hormone into the bloodstream. The analog therefore operates through a receptor pathway that already exists for the body's own releasing hormone, rather than through an engineered artificial target.
Receptor level activity follows the canonical GHRH pathway. The peptide binds the GHRH receptor, a class B G protein coupled receptor on somatotroph cells of the anterior pituitary. Binding raises intracellular cyclic AMP, which promotes calcium entry and the release of growth hormone into the bloodstream. Because the molecule acts at the same receptor as the endogenous hormone, its effect is superimposed on the natural pulsatile rhythm rather than replacing it. Whether sustained receptor occupation leads to desensitization is not fully settled.
CJC-1295 belongs to a class of synthetic peptides modeled on growth hormone releasing hormone, a forty-four amino acid signal produced by the hypothalamus. The compound is built from the first twenty-nine residues of the natural sequence, with four substitutions introduced at positions 2, 8, 15 and 27. These changes were designed to slow enzymatic breakdown while preserving receptor activation. The result is a peptide that is shorter than native GHRH and considerably more resistant to ordinary clearance pathways in circulation.
Enzymatic protection is a separate mechanism from plasma protein binding. The four substitutions in the backbone reduce recognition by dipeptidyl peptidase IV, which normally cleaves the natural hormone within minutes. Without the reactive group, this resistance still yields only a short window of activity, generally reported in the range of tens of minutes. With it, reported half-lives in early human work extended to several days. The size of that gap is the main practical distinction between the two materials.
Both forms act at the pituitary receptor for growth hormone-releasing hormone and increase growth hormone output, which in turn raises insulin-like growth factor 1. A long-acting analog produces sustained rather than pulsatile stimulation, and the physiological consequences of that pattern are not fully settled. Published human data on the extended form remain limited, and much of what circulates in discussion traces to early company reports rather than independent replication. How sustained exposure affects normal feedback remains an open question.
The distinguishing feature of the DAC form is a maleimide-containing group that reacts with the free thiol of cysteine-34 on human serum albumin. This reaction forms a covalent bond without enzymatic assistance, and it takes place after the peptide enters the bloodstream. Because albumin is abundant and long-lived, the attached peptide is carried through circulation far longer than an unmodified fragment would survive. The chemistry is a deliberate pharmacokinetic strategy rather than a change to receptor activity.
CJC-1295 acts at the growth hormone-releasing hormone receptor, a G-protein-coupled receptor found on somatotroph cells in the anterior pituitary. Binding triggers a rise in cyclic AMP and calcium entry, which promotes release of stored growth hormone. Because the peptide mimics the body's own releasing hormone, it amplifies existing secretory pulses rather than driving continuous output. The size of the response therefore depends partly on the subject's own hormonal rhythm and feedback state.
The attached maleimide group explains the unusual duration of the DAC version. After injection it reacts with the thiol of cysteine-34 on serum albumin, forming a stable covalent bond. The resulting conjugate is too large for rapid kidney filtration and is shielded from many peptidases. Reported half-lives for this form reach several days, whereas the version without the group is cleared in roughly half an hour. That gap is the main pharmacological difference between the two.
This amalgam was then heated in an atmosphere of hydrogen gas to remove the mercury, leaving pure radium metal. Later that same year, E. Ebler isolated radium metal by thermal decomposition of its azide, Ra(N3)2. Radium metal was first industrially produced at the beginning of the 20th century by Biraco, a subsidiary company of Union Minière du Haut Katanga (UMHK) in its Olen plant in Belgium. The metal became an important export of Belgium from 1922 up until World War II. The general historical unit for radioactivity, the curie, is based on the radioactivity of 226Ra. It was originally defined as the radioactivity of one gram of radium-226, but the definition was later refined to be 3.7×1010 disintegrations per second.
Shorter HRTs support the development of non-exoelectrogenous bacteria which can reduce the Coulombic efficiency electrochemical performance of the fuel cell if the anodophiles must compete for resources or if they do not have ample time to effectively degrade nutrients.
=== Metabolic manipulation === Engineering of metabolic processes have been achieved through cell-free systems. Bujara et al., for example, were able to use glycolytic network extracts, consisting of enzymes from E. coli that produced dihydroxyacetone phosphate, to analyze in real-time the metabolite concentrations while altering enzyme levels, with the result of optimal production of dihydroxyacetone phosphate. Further, Calhoun and Swartz were able to use a glycolytic intermediate to fuel a cell-free system, enabling relatively inexpensive ATP generation compared to reagent usage in phosphoenolpyruvate reactions.
Photosynthesis is a system of biological processes by which photopigment-bearing autotrophic organisms, such as most plants, algae and cyanobacteria, convert light energy—typically from sunlight—into the chemical energy necessary to fuel their metabolism. The term photosynthesis usually refers to oxygenic photosynthesis, a process that releases oxygen as a byproduct of water splitting. Photosynthetic organisms store the converted chemical energy within the bonds of intracellular organic compounds (complex compounds containing carbon), typically carbohydrates like sugars (mainly glucose, fructose and sucrose), starches, phytoglycogen and cellulose. When needing to use this stored energy, an organism's cells then metabolize the organic compounds through cellular respiration. Photosynthesis plays a critical role in producing and maintaining the oxygen content of the Earth's atmosphere, and it supplies most of the biological energy necessary for complex life on Earth. Some organisms also perform anoxygenic photosynthesis, which does not produce oxygen. Some bacteria (e.g. purple bacteria) use bacteriochlorophyll to split hydrogen sulfide as a reductant instead of water, releasing sulfur instead of oxygen, which was a dominant form of photosynthesis in the euxinic Canfield oceans during the Boring Billion.
Sources: en.wikipedia.org
Historically, the illicit drug trade in Colombia had strong connections to right-wing paramilitaries like the United Self-Defenders of Colombia (AUC) and leftist guerilla groups like the Revolutionary Armed Forces of Colombia (FARC), thus US anti-drug efforts in the country overlapped with support for counterinsurgency efforts. In the late 1960s, when drug smuggling to the US from Mexico rose to a major scale, the two governments cooperated in the launch of the Mexican drug war; the market disruption gave Colombian traffickers an opportunity to fill US demand for cannabis. Until the 1970s, Colombia "had played no major role in the production and circulation of illegal drugs in the hemisphere". After a military coup in Chile in 1973 and the spread of political repression through the Southern Cone countries disrupted cocaine smuggling from Peru and Bolivia, Colombia stepped in to fill the demand for cocaine. Pressed by the US, the Colombian government, under president Misael Pastrana (1970–1974), worked with the newly formed DEA to establish the future path for the country's war on drugs. During the 1970s, the "marijuana boom" dominated Colombia's drug trade, peaking mid-decade. That soon gave way to cocaine and the rise of the infamous Medellin and Cali Cartels that grew through the 1980s and early 1990s to dominate the global cocaine market. By the end of the century, the brutal anti-drug war left the security situation in Colombia in critical condition.
=== Metabolic dysfunction–associated steatotic liver disease === A 2023 systematic review reported that GLP-1 agonists are as effective a treatment for metabolic dysfunction–associated steatotic liver disease (MASLD) as the medications in current use, pioglitazone and vitamin E. It noted a reduction in steatosis, ballooning necrosis, lobular inflammation, and fibrosis. Wegovy (semaglutide) is approved by the FDA to treat MASH (metabolic dysfunction-associated steatohepatitis) with stage 2 or stage 3 liver fibrosis. The mechanism of action for this treatment is under investigation, but part 1 of its stage 3 clinical trials saw a 60% reduction in liver inflammation. Clinical trials are ongoing.
== Presentation == Phenotypes of spondyloepiphyseal dysplasia congenita vary. Defining features include short stature, with a short spine and neck, a barrel chest, and normal-sized hands and feet. This type of dwarfism is characterized by a normal spinal column length relative to the femur bone. Adult height ranges from 0.9 meters (35 inches) to just over 1.4 meters (55 inches). Curvature of the spine (such as kyphoscoliosis and lordosis) progresses during childhood and can cause problems with breathing. Changes in the spinal bones (vertebrae) in the neck may also increase the risk of spinal cord damage. Other skeletal signs include flattened vertebrae (platyspondyly), a hip joint deformity in which the upper leg bones turn inward (coxa vara), and an inward- and downward-turning foot (called clubfoot). Decreased joint mobility and arthritis often develop early in life. Medical texts often state a mild and variable change to facial features, including cheekbones close to the nose appearing flattened, although this appears to be unfounded. Some infants are born with a cleft palate. Severe nearsightedness (high myopia) is sometimes present, as are other eye problems that can affect vision such as detached retinas. About one-quarter of people with this condition have mild to moderate hearing loss.
== Epidemiology == Tendon injury and resulting tendinopathy are responsible for up to 30% of consultations to sports doctors and other musculoskeletal health providers. Tendinopathy is most often seen in tendons of athletes either before or after an injury but is becoming more common in non-athletes and sedentary populations. For example, the majority of patients with Achilles tendinopathy in a general population-based study did not associate their condition with a sporting activity. In another study the population incidence of Achilles tendinopathy increased sixfold from 1979–1986 to 1987–1994. The incidence of rotator cuff tendinopathy ranges from 0.3% to 5.5% and annual prevalence from 0.5% to 7.4%.
== Type XVIII Collagen and Knobloch Syndrome == Knobloch Syndrome is a type of inherited autosomal recessive disorder in which a mutation occurs in the endostatin COL18A1 protein encoding gene, which codes for production of type XVIII collagen. It is speculated that the mutation of type XVIII collagen that occurs in Knobloch syndrome can be located in several variants of endostatin, a gene that interacts with type XVIII collagen to not only develop the ocular system, but to also maintain its visual functionality. Evidence has been found for Knobloch syndrome development in genomes containing no mutations in the COL18A1 gene, and thus different variants of endostatin genes can also be responsible for the disease. One such variant of endostatin genes is the D1437N gene, which occurs after two mutations in the COL18A1 gene: the first is a one-base pair mutation insertion, and the other is an amino acid substitution of a conserved amino acid of endostatin. This amino acid substitution is deleterious because it blocks the endostatin variant from interacting with laminin. This discovery was significant in that it provided a new genetic locus for Knobloch syndrome, which helped to explain the development of the disease from genomes free of mutation in the COL18A1 gene. The mutations in type XVIII collagen result in a multitude of abnormalities in vision and eye structure, some of which include high myopia, vitreoretinal degeneration, retinal detachment, macular abnormalities, and occipital encephalocele.
Sources: en.wikipedia.org
== Structure == Type III collagen is synthesized by cells as a pre-procollagen; the human preproα1(III) chain is 1466 amino acids long, comprising an N-terminal signal peptide (residues 1–23), an N-terminal propeptide, the roughly 1000-residue triple-helical domain, and a C-terminal propeptide. The signal peptide is cleaved off producing a procollagen molecule. Three identical type III procollagen chains come together at the carboxy-terminal ends, and the structure is stabilized by the formation of disulphide bonds. Each individual chain folds into a left-handed helix and the three chains are then wrapped together into a right-handed superhelix, the triple helix. Prior to assembling the super-helix, each monomer is subjected to a number of post-translational modifications that occur while the monomer is being translated. First, on the order of 145 prolyl residues of the 239 in the triple-helical domain are hydroxylated to 4-hydroxyproline by prolyl-4-hydroxylase. Second, some of the lysine residues are hydroxylated or glycosylated, and some lysine as well as hydroxylysine residues undergo oxidative deamination catalysed by lysyl oxidase. Other post-translational modifications occur after the triple helix is formed. The large globular domains from both ends of the molecule are removed by C- and amino(N)-terminal-proteinases to generate triple-helical type III collagen monomers called tropocollagen. In addition, crosslinks form between certain lysine and hydroxylysine residues.
==== Collagen ==== Collagen is the most abundant protein in the ECM, and is the most abundant protein in the human body. It accounts for 90% of bone matrix protein content. Collagens are present in the ECM as fibrillar proteins and give structural support to resident cells. Collagen is exocytosed in precursor form (procollagen), which is then cleaved by procollagen proteases to allow extracellular assembly. Disorders such as Ehlers–Danlos syndrome, osteogenesis imperfecta, and epidermolysis bullosa are linked with genetic defects in collagen-encoding genes. The collagen can be divided into several families according to the types of structure they form:
=== Umbilical === Humans and other placental mammals have an umbilical scar (commonly referred to as a belly button or navel) which starts to heal when the umbilical cord is cut after birth. Egg-laying animals have an umbilical scar which, depending on the species, may remain visible for life or disappear within a few days after birth.
== Synthesis == To begin, this type of collagen is synthesized by the assembly of a specific trimer, when the three NC1 domains initiate molecular interactions between the three α-chains. Protomer trimerization then proceeds from the carboxy terminus to yield the fully assembled protomer. The next step in assembly is collagen IV dimerization. Two collagen IV protomers associate through the carboxy-terminal NC1 trimer to form the NC1 hexamer. These interactions form the core of the type IV collagen scaffold. The scaffold evolves into a collagen IV superstructure by "end-to-end" and lateral connections between collagen IV protomers. The collagen molecule is then formed. Lastly, the type IV collagen molecules bind together to form a complex protein network. To summarize, the process of collagen synthesis occurs mainly in the cells of fibroblasts which are specialized cells with the main function of synthesizing collagen. Collagen synthesis occurs both intracellularly and extracellularly. However, when looking specifically at type IV collagen, it is mostly synthesized extracellularly.
Collagen induction therapy (CIT), also known as microneedling, dermarolling, or skin needling, is a cosmetic procedure that involves repeatedly puncturing the skin with tiny, sterile needles (microneedling the skin). It is important to distinguish CIT from other contexts in which microneedling devices are used on the skin (e.g., transdermal drug delivery, vaccination). It is a technique for which research is ongoing, but has been used for a number of skin problems including scarring and acne. Some studies have also shown that when combined with minoxidil treatment, microneedling is able to treat hair loss more effectively than minoxidil treatment alone.
Sources: en.wikipedia.org
Reported values cluster in the range of several days, reflecting slow release from the albumin complex. Estimates differ across species and assay platforms. The figure describes circulation time in study settings rather than a fixed property.
Typical endpoints include growth hormone pulse frequency and amplitude, together with insulin-like growth factor 1 concentration. Some protocols add body composition or metabolic markers. Interpretation depends on baseline hormonal status, which varies widely between individuals.
Most human data come from small, early-stage studies, and independent replication is limited. Short-term effects on growth hormone release are documented; longer-term outcomes are not well characterized. Open questions include changes in pituitary responsiveness after repeated exposure.
It acts on the growth hormone-releasing hormone receptor found on pituitary somatotroph cells. Activation of that receptor triggers growth hormone release through a cyclic AMP dependent pathway.